Immuneering IMRX Income Statement (2020-2026)

NASDAQ IMRX
$3.73 +0.08 (+2.33%)
As of: Nov 10, 2026 · 1:10 PM EST
Reported Financials

Immuneering Quarterly Income Statement

Periods 26 quarters
Latest Sep 2026

Immuneering reported net income of -$24.58M for the quarter ended Sep 2026. This income statement covers 26 quarters of results from Jun 2020 through Sep 2026, standardized by Business Quant from the company’s SEC filings.

Income StatementIncome Statement Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026 Sep2026
Revenue & cost
Revenue
0.19M0.18M0.09M0.04M455.00
Cost of RevenueCost of Rev
0.21M0.09M0.05M0.02M
Gross Profit
-0.02M0.09M0.05M0.02M455.00
Operating items
Amortization - Intangibles
0.01M0.01M0.01M0.01M0.01M0.01M0.01M0.01M0.01M0.01M0.01M0.01M0.01M0.01M0.01M0.01M0.01M0.01M0.01M
Research & DevelopmentR&D
7.95M9.06M7.98M9.36M9.87M10.21M9.45M10.05M11.91M11.20M10.65M11.25M14.86M11.47M10.45M10.87M9.25M10.65M14.00M20.72M
Selling, General & AdministrativeSG&A
3.15M3.95M3.70M3.84M4.11M4.46M4.04M3.87M4.38M4.12M4.25M4.01M3.69M4.01M4.30M4.51M4.49M4.68M5.00M5.06M
Other Operating ExpensesOther Opex
0.01M0.01M0.01M0.01M0.01M0.01M0.01M0.01M0.01M0.01M0.01M0.01M0.01M0.01M0.01M0.01M0.01M0.01M0.01M
Operating ExpensesOpex
11.10M13.02M11.69M13.21M13.99M14.68M13.50M13.93M16.30M15.33M14.91M15.27M18.56M15.48M14.76M15.38M13.75M15.34M19.00M25.79M
Operating IncomeOp. Inc
-11.12M-12.93M-11.65M-13.19M-13.99M-14.68M-13.50M-13.93M-16.30M-15.33M-14.91M-15.27M-18.56M-15.48M-14.76M-15.38M-13.75M-15.34M-19.00M-25.79M
Non-operating items
Gains (Losses) on Sale of Assets & InvestmentsGains on Sales
-0.04M-0.12M-0.01M0.04M0.11M
Interest & Investment IncomeInt & Inv Inc
0.14M0.13M0.14M0.22M0.52M0.83M1.17M0.86M0.75M0.80M0.83M0.55M0.42M0.44M0.32M0.42M1.86M1.36M1.08M1.20M
Other Non Operating IncomeOther Non Op Inc.
-0.12M-0.10M-0.02M0.12M0.22M0.24M0.15M0.48M0.46M0.21M0.01M0.13M0.09M0.31M0.51M0.65M0.39M
Net income details
EBIT
-11.12M-12.93M-11.65M-13.19M-13.99M-14.68M-13.50M-13.93M-16.30M-15.33M-14.91M-15.27M-18.56M-15.48M-14.76M-15.38M-13.75M-15.34M-19.00M-25.79M
EBT
-10.97M-12.79M-11.50M-12.97M-13.47M-13.85M-12.34M-13.07M-15.55M-14.52M-14.09M-14.73M-18.14M-15.05M-14.43M-14.96M-11.89M-13.97M-17.92M-24.58M
Income After Tax
-10.97M-12.79M-11.50M-12.97M-13.47M-13.85M-12.34M-13.07M-15.55M-14.52M-14.09M-14.73M-18.14M-15.05M-14.43M-14.96M-11.89M-13.97M-17.92M-24.58M
Income from Continuing OperationsIncome (Continuing)
-10.97M-12.79M-11.50M-12.97M-13.47M-13.85M-12.34M-13.07M-15.55M-14.52M-14.09M-14.73M-18.14M-15.05M-14.43M-14.96M-11.89M-13.97M-17.92M-24.58M
Consolidated Net IncomeConsol Net Inc.
-10.97M-12.79M-11.50M-12.97M-13.47M-13.85M-12.34M-13.07M-15.55M-14.52M-14.09M-14.73M-18.14M-15.05M-14.43M-14.96M-11.89M-13.97M-17.92M-24.58M
Income towards Parent CompanyParent Net Inc
-10.78M-12.90M-11.53M-12.84M-13.25M-13.60M-12.19M-12.60M-15.08M-14.31M-14.08M-14.60M-18.05M-15.05M-14.43M-14.96M-11.58M-13.46M-17.27M-24.19M
Net Income towards Common StockholdersNet Income
-10.78M-12.90M-11.53M-12.84M-13.25M-13.60M-12.19M-12.60M-15.08M-14.31M-14.08M-14.60M-18.05M-15.05M-14.43M-14.96M-11.58M-13.46M-17.27M-24.19M
Additional items
EPS (Basic)
-0.79-0.49-0.44-0.49-0.50-0.51-0.43-0.43-0.53-0.49-0.47-0.49-0.60-0.42-0.40-0.38-0.26-0.21-0.27-0.37
EPS (Diluted)
-0.79-0.49-0.44-0.49-0.50-0.51-0.43-0.43-0.53-0.49-0.47-0.49-0.60-0.42-0.40-0.38-0.26-0.21-0.27-0.37
Shares Outstanding
13.61M26.36M26.39M26.39M26.39M26.44M28.65M29.27M28.42M29.37M29.65M29.84M29.98M35.53M35.99M39.67M44.01M64.66M64.70M64.71M
Shares Outstanding (Diluted)Shares Outstanding (Dil.)
13.61M26.36M26.39M26.39M26.39M26.44M28.65M29.27M28.42M29.37M29.65M29.84M29.98M35.53M35.99M39.67M44.01M64.66M64.70M64.71M
Shares Outstanding (Entity)Shares Outstanding (Entity.)
13.61M26.38M26.39M26.40M26.42M26.50M29.26M29.27M29.27M29.65M29.65M31.05M31.05M35.99M35.99M39.67M44.01M64.69M64.70M64.76M
EBITDA
-11.10M-12.87M-11.58M-13.11M-13.90M-14.60M-13.42M-13.84M-16.20M-15.23M-14.82M-15.18M-18.46M-15.39M-14.67M-15.29M-13.67M-15.25M-18.91M-25.69M

Immuneering Income Statement API

Pull Immuneering's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=IMRX&statement=IS&frequency=Quarter&period=all&api_key=YOUR_API_KEY